Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Mansun Law; Toshiaki Maruyama; Jamie Lewis; Erick Giang; Alexander W. Tarr; Zania Stamataki; Pablo Gastaminza; Francis V. Chisari; Ian M. Jones; Robert I. Fox; Jonathan Ball; Jane A. McKeating; Norman M. Kneteman; Dennis R. Burton

doi:10.1038/nm1698

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Mansun Law
, Toshiaki Maruyama
, Jamie Lewis
, Erick Giang
, Alexander W. Tarr
, Zania Stamataki
, Pablo Gastaminza
, Francis V. Chisari
, Ian M. Jones
, Robert I. Fox
, Jonathan Ball
, Jane A. McKeating
, Norman M. Kneteman
, Dennis R. Burton

Research output: Contribution to journal › Article › peer-review

538 Citations (Scopus)

Abstract

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

Original language	English
Pages (from-to)	25-27
Number of pages	3
Journal	Nature Medicine
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/nm1698
Publication status	Published - 1 Jan 2008
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/nm1698

Cite this

@article{91b653d5b28a4550b75e9ff241d5bfc7,

title = "Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge",

abstract = "A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.",

author = "Mansun Law and Toshiaki Maruyama and Jamie Lewis and Erick Giang and Tarr, \{Alexander W.\} and Zania Stamataki and Pablo Gastaminza and Chisari, \{Francis V.\} and Jones, \{Ian M.\} and Fox, \{Robert I.\} and Jonathan Ball and McKeating, \{Jane A.\} and Kneteman, \{Norman M.\} and Burton, \{Dennis R.\}",

year = "2008",

month = jan,

day = "1",

doi = "10.1038/nm1698",

language = "English",

volume = "14",

pages = "25--27",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

AU - Law, Mansun

AU - Maruyama, Toshiaki

AU - Lewis, Jamie

AU - Giang, Erick

AU - Tarr, Alexander W.

AU - Stamataki, Zania

AU - Gastaminza, Pablo

AU - Chisari, Francis V.

AU - Jones, Ian M.

AU - Fox, Robert I.

AU - Ball, Jonathan

AU - McKeating, Jane A.

AU - Kneteman, Norman M.

AU - Burton, Dennis R.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

AB - A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

U2 - 10.1038/nm1698

DO - 10.1038/nm1698

M3 - Article

SN - 1078-8956

VL - 14

SP - 25

EP - 27

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this